The U.S. Food and Drug Administration approved oral upadacitinib for giant cell arteritis based on phase III trial data, showing higher rates of remission compared to placebo. It offers an alternative treatment option with safety considerations for serious infections and cardiovascular events.
Source: AbbVie
